Activartis’ Cancer Immunotherapy Receives Orphan Drug Designation from FDA
|| Print ||
|Monday, 01 July 2013 13:00 (UTC + 2)|
Vienna, Austria, July 1, 2013 / B3C newswire / - The US FDA notified the Austrian biotech company Activartis on Wednesday, June 26th, that Orphan Drug Designation (ODD) has been granted for its innovative Cancer Immunotherapy AV0113. The ODD applies specifically to the use of AV0113 for the treatment of malignant glioma, a very aggressive type of brain cancer. The European drug agency EMA already granted ODD at the end of last year.
In principle, Activartis’ AV0113 Cancer Immunotherapy may be used to fight any type of cancer. The individualized therapeutic technology is based on a patented procedure in which a cancer patient’s immune system is primed to fight the tumor and eventually control its growth. This concept is based on the use of Dendritic Cells, the key regulatory elements of the immune system, that are the same as the tumor tissue derived from the patient.
Active cancer immunotherapy based on Dendritic Cells
The Dendritic Cells are charged with tumor-derived antigens, determinants that distinguish a tumor cell from a normal cell. These antigens are processed by the Dendritic Cell and shuttled to the cell surface in order to present them to T-cells. This, however, is not sufficient to prime an immune response against the tumor antigens. The “trick” referred to above is contacting Dendritic Cells with a microbial danger signal. Certain molecules that are present in microorganisms but not in higher organisms signal to the Dendritic Cell the presence of a microbial invasion in its surroundings and hence danger to the organism.
As tumor cells originate from a cancer patient’s normal cells, they do not provide danger molecules which are recognized by the Dendritic Cell. The critical and unique part of Activartis’ AV0113 technology is exposing tumor antigen-charged Dendritic Cells to one of these danger molecules: lipopolysaccharides, the bacterial endotoxins. This causes the Dendritic Cell to assume a potently immune stimulatory and pro-inflammatory mode of action. Upon returning these Dendritic Cells to the patient, they activate tumor-specific T-cells, most importantly the so-called cytotoxic T-cells, which become able to recognize and destroy tumor cells.
Early results of the Activartis AV0113 trial reveal a promising trend.
Confirmation of that trend is expected by the end of 2013. If the trend currently observed is confirmed, AV0113 is bound to become part of the standard therapy for GBM.
Activartis Biotech GmbH